Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Monitoring of radiologic disease activity by serum neurofilaments in MS

T. Uher, S. Schaedelin, B. Srpova, C. Barro, N. Bergsland, M. Dwyer, M. Tyblova, K. Vodehnalova, P. Benkert, J. Oechtering, D. Leppert, Y. Naegelin, J. Krasensky, M. Vaneckova, E. Kubala Havrdova, L. Kappos, R. Zivadinov, D. Horakova, J. Kuhle,...

. 2020 ; 7 (4) : . [pub] 20200409

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026727

OBJECTIVE: To determine whether serum neurofilament light chain (sNfL) levels are associated with recent MRI activity in patients with relapsing-remitting MS (RRMS). METHODS: This observational study included 163 patients (405 samples) with early RRMS from the Study of Early interferon-beta1a (IFN-β1a) Treatment (SET) cohort and 179 patients (664 samples) with more advanced RRMS from the Genome-Wide Association Study of Multiple Sclerosis (GeneMSA) cohort. Based on annual brain MRI, we assessed the ability of sNfL cutoffs to reflect the presence of combined unique active lesions, defined as new/enlarging lesion compared with MRI in the preceding year or contrast-enhancing lesion. The probability of active MRI lesions among patients with different sNfL levels was estimated with generalized estimating equations models. RESULTS: From the sNfL samples ≥90th percentile, 81.6% of the SET (OR = 3.4, 95% CI = 1.8-6.4) and 48.9% of the GeneMSA cohort samples (OR = 2.6, 95% CI = 1.7-3.9) was associated with radiological disease activity on MRI. The sNfL level between the 10th and 30th percentile was reflective of negligible MRI activity: 1.4% (SET) and 6.5% (GeneMSA) of patients developed ≥3 active lesions, 5.8% (SET) and 6.5% (GeneMSA) developed ≥2 active lesions, and 34.8% (SET) and 11.8% (GeneMSA) showed ≥1 active lesion on brain MRI. The sNfL level <10th percentile was associated with even lower MRI activity. Similar results were found in a subgroup of clinically stable patients. CONCLUSIONS: Low sNfL levels (≤30th percentile) help identify patients with MS with very low probability of recent radiologic disease activity during the preceding year. This result suggests that in future, sNfL assessment may substitute the need for annual brain MRI monitoring in considerable number (23.1%-36.4%) of visits in clinically stable patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026727
003      
CZ-PrNML
005      
20240903114739.0
007      
ta
008      
211013s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1212/NXI.0000000000000714 $2 doi
035    __
$a (PubMed)32273481
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Uher, Tomas $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic
245    10
$a Monitoring of radiologic disease activity by serum neurofilaments in MS / $c T. Uher, S. Schaedelin, B. Srpova, C. Barro, N. Bergsland, M. Dwyer, M. Tyblova, K. Vodehnalova, P. Benkert, J. Oechtering, D. Leppert, Y. Naegelin, J. Krasensky, M. Vaneckova, E. Kubala Havrdova, L. Kappos, R. Zivadinov, D. Horakova, J. Kuhle, T. Kalincik
520    9_
$a OBJECTIVE: To determine whether serum neurofilament light chain (sNfL) levels are associated with recent MRI activity in patients with relapsing-remitting MS (RRMS). METHODS: This observational study included 163 patients (405 samples) with early RRMS from the Study of Early interferon-beta1a (IFN-β1a) Treatment (SET) cohort and 179 patients (664 samples) with more advanced RRMS from the Genome-Wide Association Study of Multiple Sclerosis (GeneMSA) cohort. Based on annual brain MRI, we assessed the ability of sNfL cutoffs to reflect the presence of combined unique active lesions, defined as new/enlarging lesion compared with MRI in the preceding year or contrast-enhancing lesion. The probability of active MRI lesions among patients with different sNfL levels was estimated with generalized estimating equations models. RESULTS: From the sNfL samples ≥90th percentile, 81.6% of the SET (OR = 3.4, 95% CI = 1.8-6.4) and 48.9% of the GeneMSA cohort samples (OR = 2.6, 95% CI = 1.7-3.9) was associated with radiological disease activity on MRI. The sNfL level between the 10th and 30th percentile was reflective of negligible MRI activity: 1.4% (SET) and 6.5% (GeneMSA) of patients developed ≥3 active lesions, 5.8% (SET) and 6.5% (GeneMSA) developed ≥2 active lesions, and 34.8% (SET) and 11.8% (GeneMSA) showed ≥1 active lesion on brain MRI. The sNfL level <10th percentile was associated with even lower MRI activity. Similar results were found in a subgroup of clinically stable patients. CONCLUSIONS: Low sNfL levels (≤30th percentile) help identify patients with MS with very low probability of recent radiologic disease activity during the preceding year. This result suggests that in future, sNfL assessment may substitute the need for annual brain MRI monitoring in considerable number (23.1%-36.4%) of visits in clinically stable patients.
650    _2
$a dospělí $7 D000328
650    _2
$a kohortové studie $7 D015331
650    12
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a relabující-remitující roztroušená skleróza $x krev $x diagnóza $x patologie $7 D020529
650    _2
$a neurofilamentové proteiny $x krev $7 D016900
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Schaedelin, Sabine $u Clinical Trial Unit, Department of Clinical Research, University Hospital Basel, University of Basel
700    1_
$a Srpová, Barbora $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic $7 xx0321726
700    1_
$a Barro, Christian $u Departments of Medicine, Biomedicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Switzerland
700    1_
$a Bergsland, Niels $u Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, Buffalo Neuroimaging Analysis Center, University at Buffalo, State University of New York, Buffalo
700    1_
$a Dwyer, Michael $u Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, Buffalo Neuroimaging Analysis Center, University at Buffalo, State University of New York, Buffalo
700    1_
$a Tyblova, Michaela $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic
700    1_
$a Vodehnalova, Karolina $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic
700    1_
$a Benkert, Pascal $u Clinical Trial Unit, Department of Clinical Research, University Hospital Basel, University of Basel
700    1_
$a Oechtering, Johanna $u Departments of Medicine, Biomedicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Switzerland
700    1_
$a Leppert, David $u Departments of Medicine, Biomedicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Switzerland
700    1_
$a Naegelin, Yvonne $u Departments of Medicine, Biomedicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Switzerland
700    1_
$a Krasensky, Jan $u Department of Radiology, Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague, Czech Republic
700    1_
$a Vaneckova, Manuela $u Department of Radiology, Charles University in Prague, First Faculty of Medicine and General University Hospital in Prague, Czech Republic
700    1_
$a Kubala Havrdova, Eva $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic
700    1_
$a Kappos, Ludwig $u Departments of Medicine, Biomedicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Switzerland
700    1_
$a Zivadinov, Robert $u Center for Biomedical Imaging at Clinical Translational Science Institute, University at Buffalo, State University of New York, NY
700    1_
$a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic
700    1_
$a Kuhle, Jens $u Departments of Medicine, Biomedicine and Clinical Research, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Switzerland
700    1_
$a Kalincik, Tomas $u Department of Neurology, The Royal Melbourne Hospital, Victoria, Australia
773    0_
$w MED00186373 $t Neurology® neuroimmunology & neuroinflammation $x 2332-7812 $g Roč. 7, č. 4 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32273481 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20240903114736 $b ABA008
999    __
$a ok $b bmc $g 1715463 $s 1147234
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 7 $c 4 $e 20200409 $i 2332-7812 $m Neurology® neuroimmunology & neuroinflammation $n Neurol Neuroimmunol Neuroinflamm $x MED00186373
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...